Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma

被引：0
|
作者：
Omar Eton
Merrick I Ross
Mary Jo East
Paul F Mansfield
Nicholas Papadopoulos
Julie A Ellerhorst
Agop Y Bedikian
Jeffrey E Lee
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Melanoma Medical Oncology
[2] The University of Texas MD Anderson Cancer Center,Department of Surgical Oncology
[3] The University of Texas MD Anderson Cancer Center,Department of Experimental Therapeutics
来源：
Journal of Translational Medicine | / 8卷
关键词：
Melanoma; Major Histocompatibility Complex Class; Adjuvant Setting; ELISPOT Assay; Autologous Tumor Cell;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Safety and efficacy of heat shock protein-peptide 96 complex (HSPPC-96) vaccine therapy in patients with relapsed or previously untreated low-grade non-Hodgkin lymphoma.
    Younes, A
    Fayad, L
    Pro, B
    McLaughlin, P
    Hagemeister, F
    Mansfield, P
    Clayman, G
    Medeiros, LJ
    Manning, J
    Lewis, J
    Srivastava, P
    BLOOD, 2003, 102 (11) : 898A - 899A
  • [22] Autologous heat shock protein vaccine (HSPPC-96) for patients with recurrent glioblastoma (GBM): Results of a phase II multicenter clinical trial with immunological assessments.
    Parsa, A.
    Crane, C.
    Han, S.
    Kivett, V.
    Fedoroff, A.
    Butowski, N. A.
    Chang, S. M.
    Clarke, J. L.
    Berger, M. S.
    McDermott, M.
    Aghi, M.
    Yanes, C.
    Prados, M.
    Sloan, A. E.
    Bruce, J. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Heat shock protein peptide complex 96-based vaccines in melanoma
    di Pietro, Alessandra
    Tosti, Giulio
    Ferrucci, Pier Francesco
    Testori, Alessandro
    HUMAN VACCINES, 2009, 5 (11): : 727 - 737
  • [24] Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial
    Ji, Nan
    Zhang, Yang
    Liu, Yunpeng
    Xie, Jian
    Wang, Yi
    Hao, Shuyu
    Gao, Zhixian
    JCI INSIGHT, 2018, 3 (10):
  • [25] Natural killer and NK-Like T-Cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96
    Pilla, L
    Squarcina, P
    Coppa, J
    Mazzaferro, V
    Huber, V
    Pende, D
    Maccalli, C
    Sovena, G
    Mariani, L
    Castelli, C
    Parmiani, G
    Rivoltini, L
    CANCER RESEARCH, 2005, 65 (09) : 3942 - 3949
  • [26] A phase II study of heat shock protein-peptide complex-96 vaccine therapy in patients with indolent non-Hodgkin's lymphoma
    Younes, A
    CLINICAL LYMPHOMA, 2003, 4 (03): : 183 - 185
  • [27] Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations
    Tamura, Y
    Peng, P
    Liu, K
    Daou, M
    Srivastava, PK
    SCIENCE, 1997, 278 (5335) : 117 - 120
  • [28] Active specific immunotherapy in patients with renal cell carcinoma using autologus tumor derived heat shock protein peptide complex 96 vaccine
    Amato, RJ
    Savary, C
    Tomasovic, S
    Reitsma, D
    Hawkins, E
    Srivastava, PK
    CELL STRESS & CHAPERONES, 2000, 5 (04): : 373 - 373
  • [29] HBV-specific peptide associated with heat-shock protein gp96
    Meng, SD
    Gao, T
    Gao, GF
    Tien, P
    LANCET, 2001, 357 (9255): : 528 - 529
  • [30] Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 study group
    Testori, Alessandro
    Richards, Jon
    Whitman, Eric
    Mann, G. Bruce
    Lutzky, Jose
    Camacho, Luis
    Parmiani, Giorgio
    Tosti, Giulio
    Kirkwood, John M.
    Hoos, Axel
    Yuh, Lianng
    Gupta, Renu
    Srivastava, Pramod K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) : 955 - 962
12345